Stay updated on Daratumumab Dose Schedules in Smoldering Multiple Myeloma Clinical Trial
Sign up to get notified when there's something new on the Daratumumab Dose Schedules in Smoldering Multiple Myeloma Clinical Trial page.

Latest updates to the Daratumumab Dose Schedules in Smoldering Multiple Myeloma Clinical Trial page
- ChecktodayChange DetectedThe study record’s results section was updated to show newly posted study results (dated 2026-04-23) and corresponding changes to multiple outcome measures. These include efficacy endpoints like complete response by IMWG, MRD negativity, progression/death and PFS measures, time to next treatment, response to first subsequent treatment, symptomatic progression with adverse prognostic features, and overall survival definitions/figures.SummaryDifference2%

- Check7 days agoChange DetectedAdded Multiple myeloma as a topic and related topics (MedlinePlus Genetics). Updated page revision from v3.5.0 to v3.5.2.SummaryDifference0.2%

- Check15 days agoChange DetectedRemoved the 'Multiple myeloma' topic and related 'MedlinePlus Genetics' content from the page. This reduces the disease-specific context available to users researching the study.SummaryDifference0.1%

- Check22 days agoChange DetectedAdded related topics 'Multiple myeloma' and 'MedlinePlus Genetics' to the page.SummaryDifference0.1%

- Check29 days agoChange DetectedThe related topics section no longer includes 'Multiple myeloma' and the 'MedlinePlus Genetics' topic.SummaryDifference0.1%

- Check36 days agoChange DetectedAdded a Multiple Myeloma topic and related MedlinePlus Genetics content; updated the page revision from 3.4.3 to 3.5.0.SummaryDifference0.2%

Stay in the know with updates to Daratumumab Dose Schedules in Smoldering Multiple Myeloma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Daratumumab Dose Schedules in Smoldering Multiple Myeloma Clinical Trial page.